Literature DB >> 33787985

Shedding light on polypragmasy of pain after transurethral prostate surgery procedures: a systematic review and meta-analysis.

Marcelo Langer Wroclawski1,2,3, Daniele Castellani4, Flavio L Heldwein5, Saulo Borborema Teles6, Jonathan Doyun Cha6, Hongda Zhao7, Thomas Herrmann8,9, Vinson Wai-Shun Chan10, Jeremy Yuen-Chun Teoh7.   

Abstract

PURPOSE AND
OBJECTIVE: To evaluate and compare the incidences of post-operative pelvic pain (PPP) in patients undergoing ablation, enucleation and conventional transurethral resection of the prostate (TURP).
METHODS: A systematic review and meta-analysis was conducted according to the PRISMA guidelines. Using MEDLINE via PubMed and Cochrane CENTRAL, randomised control trials (RCTs) and observational studies reporting PPP rates post-ablation, enucleation or TURP were identified. The risk of biases (RoB) in RCTs and observation studies were assessed using the Cochrane RoB1.0 tool and the Newcastle-Ottawa Scale, respectively.
RESULTS: 62 studies were included for qualitative analysis, while 51 of them reported number of patients with PPP post-intervention. Three observational studies and 13 RCTs compared the rates of PPP in patients undergoing ablation, enucleation or TURP. The most reported types of PPP are dysuria, abdominal pain and irritative symptoms. The pooled incidence of PPP at 1-month follow-up in patients undergoing ablation, enucleation and TURP were 0.15 (95% CI 0.10-0.22), 0.09 (95% CI 0.04-0.19 and 0.10 (95% CI 0.06-0.15), respectively. PPP is no longer prevalent at 3-months and onwards post-operatively. Ablation is associated with a higher risk of PPP than enucleation (RR 2.19, 95% CI 1.04-4.62) and TURP (RR 2.40, 95% CI 1.03-5.62) in observational studies but not RCTs; and there were no significant differences in the rates of PPP upon comparison of other modalities.
CONCLUSION: PPP is common after transurethral benign prostatic hyperplasia surgery. Patients undergoing ablation had a higher rate of post-intervention PPP than those undergoing enucleation and TURP in observational studies.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Dysuria; Pain; Prostate; Prostatic hyperplasia; Transurethral resection of prostate; Urological surgical procedures

Mesh:

Year:  2021        PMID: 33787985     DOI: 10.1007/s00345-021-03678-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  78 in total

Review 1.  'Button type' bipolar plasma vaporisation of the prostate compared with standard transurethral resection: a systematic review and meta-analysis of short-term outcome studies.

Authors:  Marcelo L Wroclawski; Arie Carneiro; Rodrigo Dal Moro Amarante; Carlos E B Oliveira; Victor Shimanoe; Bianca A V Bianco; Paulo K Sakuramoto; Antonio C L Pompeo
Journal:  BJU Int       Date:  2015-10-03       Impact factor: 5.588

2.  The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives.

Authors:  G Schatzl; S Madersbacher; T Lang; M Marberger
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

3.  Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments.

Authors:  Luke A McGuinness; Julian P T Higgins
Journal:  Res Synth Methods       Date:  2020-04-26       Impact factor: 5.273

4.  Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2004

5.  Clinical comparison of two minimal invasive techniques in the treatment of benign prostatic enlargement over 90 ml: BIVAP (Richard Wolf®) saline vaporization of the prostate vs. bipolar plasmakinetic TURP.

Authors:  Ayhan Karakose
Journal:  Arch Esp Urol       Date:  2020-03       Impact factor: 0.436

6.  Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.

Authors:  Alexander Bachmann; Leander Schürch; Robin Ruszat; Stephen F Wyler; Hans-Helge Seifert; Alexander Müller; Kurt Lehmann; Tullio Sulser
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

7.  GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up.

Authors:  Abdulla Al-Ansari; Nagy Younes; Venkataramana Pai Sampige; Khalid Al-Rumaihi; Ardalan Ghafouri; Tawiz Gul; Ahmed A Shokeir
Journal:  Eur Urol       Date:  2010-05-27       Impact factor: 20.096

Review 8.  Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement.

Authors:  Sascha A Ahyai; Peter Gilling; Steven A Kaplan; Rainer M Kuntz; Stephan Madersbacher; Francesco Montorsi; Mark J Speakman; Christian G Stief
Journal:  Eur Urol       Date:  2010-06-11       Impact factor: 20.096

9.  Thulium laser vaporesection versus transurethral electrovaporization of the prostate in high-risk patients with benign prostatic hyperplasia.

Authors:  Zhaowei Zhu; Zhoujun Shen; Fanzhuo Tu; Yu Zhu; Fukang Sun; Yuan Shao; Haofei Wang; Shan Zhong; Chen Xu
Journal:  Photomed Laser Surg       Date:  2012-10-31       Impact factor: 2.796

Review 10.  Holmium laser enucleation versus simple prostatectomy for treating large prostates: Results of a systematic review and meta-analysis.

Authors:  Patrick Jones; Laith Alzweri; Bhavan Prasad Rai; Bhaskar K Somani; Chris Bates; Omar M Aboumarzouk
Journal:  Arab J Urol       Date:  2015-11-26
View more
  1 in total

Review 1.  GreenLight Laser™ Photovaporization versus Transurethral Resection of the Prostate: A Systematic Review and Meta-Analysis.

Authors:  Daniele Castellani; Giacomo Maria Pirola; Emanuele Rubilotta; Marilena Gubbiotti; Simone Scarcella; Martina Maggi; Vineet Gauhar; Jeremy Yuen-Chun Teoh; Andrea Benedetto Galosi
Journal:  Res Rep Urol       Date:  2021-05-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.